Online literature searches were performed via PubMed, PubMed Central, and Google using the keywords “immune checkpoint inhibition”; “host-directed therapy”; “T cell exhaustion”; “cancer immunotherapy”; “anti-PD-1 therapy”; “anti-PD-L1 therapy”; “chronic infections”; “antigen-specif...
Patients with positive PD-L1 expression may benefit more from anti-PD-1/PD-L1 therapy. 1st-line anti-PD-1/PD-L1 therapy can be chosen as the best modality. Squamous cell lung cancer also benefit from anti-PD-1/PD-L1 therapy.doi:10.1007/s12253-015-0011-z...
PD-L1/PD-1Immune checkpoint inhibitorTumor immune therapy, especially anti-programmed cell death ligand-1/programmed cell death-1 (PD-L1/PD-1) treatment, is currently the focus of substantial attention. Ovarian cancer is the leading cause of mortality from gynecological malignancies, and novel ...
FDA: Food and Drug Administration; Ig: immunoglobulin; mAb: monoclonal antibody; NSCLC: non-small-cell lung cancer; PD-1: programmed death-1; PD-L1: programmed death-ligand 1; PD-L2: programmed death-ligand 2. Table 2.PD-L1 IHC assay systems as companion and complementary diagnostic assays...
在《anti-PD-(L)1联合用药策略》上两集里,介绍了肿瘤免疫周期和三类肿瘤,并聚焦肿瘤免疫周期的前三个阶段—察觉 渗入和破境。在本集里,我们将讨论肿瘤免疫周期的最后阶段:歼灭。
PURPOSE: To better understand the efficacy and safety of anti-PD-1/PD-L1 therapy (atezolizumab, pembrolizumab, nivolumab) in patients with previously treated advanced non-small-cell lung cancer (NSCLC). METHODS: The Cochrane Controlled Trial Register, Embase, Medline, and the Science Citation Index...
The main challenges for programmed cell death 1(PD-1)/PD-1 ligand (PD-L1) checkpoint blockade lie in a lack of sufficient T cell infiltration, tumor immunosuppressive microenvironment, and the inadequate tumor accumulation and penetration of anti-PD-1/PD
2023年11月02日,哥伦比亚大学爱尔文医学中心的研究人员在Cancer Cell期刊发表了题为:Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer的研究文章。 与其他恶性肿瘤相比,原发性和去势抵抗性前列腺癌(CRPC)的肿瘤微环境(TME)...
Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. However, the overall response rate remains unsati
摘要: 程序性细胞死亡-1 (PD-1) 免疫检查点抑制剂在多种肿瘤中显示出良好的疗效。在这里,我们报告一个不可切除的局部进展期胃癌 (GC) 与程序性细胞死亡 ligand-1 (PD-L1) 阳性和微卫星不稳定 (MSI),作为一线治疗方案,单剂量的 anti-PD-1 联合化疗治疗后,病理完全缓解 (pCR) 表现出意想不到的疗效。一...